For U.S. Residents Only


Treating Families Affected by Fabry Disease for Over 15 Years

Fabrazyme helps people with Fabry disease by replacing a missing enzyme. It has been used to treat people with Fabry disease for over 15 years and is backed by the safety and effectiveness shown in clinical studies.


Fabrazyme® (agalsidase beta) is used to treat patients with Fabry disease. Fabrazyme lowers the amount of a substance called globotriaosylceramide (GL-3), which builds up in cells lining the blood vessels of the kidney and certain other cells.

The lowering of GL-3 suggests that Fabrazyme may improve how Fabry disease affects your body; however a relationship of lower GL-3 to specific signs and symptoms of Fabry disease has not been proven.

Charles and Amanda, Fabry Patients